Celltrion Earnings Jump Shows Stronger Growth Potential Celltrion is rated Buy as analysts expect upside; latest quarter shows revenue +36% YoY but operating profit +115% and net profit +219%, driven by U.S. biosimilar expansion. 2026년 07월 23일 English
Celltrion Earnings Soar – Strong Growth and Margin Upside Celltrion shows strong revenue growth and accelerating profits, driven by higher margin product mix and improving costs, supporting a bullish Buy consensus. 2026년 07월 03일 English
Celltrion Earnings Accelerate: Margin Gains Boost Outlook Celltrion BUY: operating profit and net income surged YoY, driven by strong margin expansion; stock near lowest target supports upside, but sustainability and valuation risk remain. 2026년 05월 08일 English
Celltrion Stock Momentum Shifts: Margin And Earnings Surge Celltrion is rated Buy as margins expand rapidly, operating profit accelerates, and three ADCs have moved to patient dosing with US fast track, supporting upside. 2026년 04월 28일 English
